The stock market is full of unproven, speculative stocks that aren't suitable for the average investor. However, if you're aware of company-specific risks and willing and able to accept the consequences, speculative stocks can occasionally turn out to be big winners for a portfolio. With that in mind, the Fool's health care bureau chief, Brenton Flynn, outlines two of 2013's best-performing (and speculative) stocks in the industry and offers a few words of caution to prospective buyers.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? He's always on the lookout for revolutionary stocks, and he recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article 2 Speculative Stocks Soaring in 2013 originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Illumina and Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.